ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Earnings Release
Annual Report to Security Holders
Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Exhibit 99.1
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-1MEF